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The molecular trigger of CNS myelination is unknown. By targeting Pten in 
cerebellar granule cells and activating the AKT1/mTOR pathway we increased 
the caliber of normally unmyelinated axons and the expression of numerous 
genes encoding regulatory proteins. Surprisingly, this led to the expansion of 
genetically wildtype OPCs, oligodendrocyte differentiation, and the de novo 
myelination of parallel fibers. Thus, a PI(3,4,5)P3-dependent neuronal program 
is sufficient to trigger all steps of myelination. 
 
In the peripheral nervous system, the 'trigger' of myelination is axon size (>1µm), a 
threshold mediated by Nrg1 type III on the axon surface1. Since Nrg1 is not required 
for CNS myelination2, we asked whether axon size can be experimentally increased 
here by the absence of PTEN3, i.e. with PI(3,4,5)P3 stimulating the AKT1/mTOR 
pathway (Fig.1a). To specifically enlarge cerebellar granule cells (GC) and their 
naturally unmyelinated parallel fiber (Pf) axons, we generated Tg(m6)-
Cre*PtenloxP/loxP mice4, 5. By reporter gene expression4, recombination begins at P9 in 
predominantly postmitotic GC. The cerebellum of Tg(m6)-Cre*PtenloxP/loxP mice 
(hereafter termed Pten cKO or ‘mutants’) revealed a loss of Pten mRNA (-63%; 
Fig.1b) and protein (-80%; n=3 each genotype; p=0.0025, t=6.788, d.f.=4, two-tailed 
unpaired Student’s t-test; Fig.1c) compared to PtenloxP/loxP mice (hereafter termed 
‘controls’) at age 3.5 months. Loss of PTEN resulted in enhanced phosphorylation of 
well-known downstream targets of the PI3K pathway (Fig.1d).  
 
Mutant mice appeared healthy (Supplementary Video1), but cerebellar GC layer (GL) 
and molecular layer (ML) progressively enlarged (Fig.1e; Supplementary Fig.1a). 
Immunostaining of GABAA receptor 6 revealed a gradual size increase of GC 
somata (Supplementary Fig.1b). Older mice developed ataxia and tremor 
(Supplementary Video2), possibly due to hamartomas at advanced age 
(Supplementary Fig.2; Supplementary Information). 
 
The diameter of Pf also increased over time, as quantified by electron microscopy 
(EM), reaching 0.61±0.009µm in mutants over 0.16±0.002 µm in controls at 1 year of 
age (Fig.1f,g; Supplementary Fig.1c). Importantly, radial Pf growth in mutant brains 
was associated with significant myelination beginning at age P40 (2.30.6% 
myelinated Pf) and progressing over time (3 months: 9.51% myelinated Pf), up to 
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403% of Pf being myelinated at 1 year with an average g-ratio of 0.84. Myelination 
was visualized by Gallyas silver impregnation (Supplementary Fig.3a), anti-CNP 
immunohistochemistry (Fig.1h, Supplementary Fig.3b), including whole-mount 
immunolabelling combined with light sheet and 2-photon microscopy (Supplementary 
Video3), as well as EM (Fig.1i-k). We determined a 'size threshold’ of approximately 
0.25 µm for myelination at all ages tested (Fig.1k,l). Myelinated Pf segments were 
very rarely seen in controls.  
 
De novo myelination included the formation of nodes and paranodes with septate -like 
junctions (Fig.1j) and the clustering of Caspr and NaV1.6 on axons (Fig.1m,n). GC 
synaptic contacts to Purkinje cell dendrites were restricted to Pf ‘nodal’ regions 
(Fig.1o; Supplementary Fig.4). 
 
The ML harbors normally very few oligodendrocytes and only scattered OPCs, as 
demonstrated in Plp1-DsRed*Ng2-EYFP double-transgenic mice (Fig.2a). In Pten 
mutants at P45, mature oligodendrocytes were increased in the GL (+33%) and more 
prominent in the ML (+750%), yet unaltered in cerebellar white matter (WM) (Fig.2b). 
To determine whether OPCs proliferate in the ML or are recruited from the GL, we 
combined immunostaining with BrdU labeling (Fig.2c). After 20 days of daily BrdU 
injections (P25-45), OPC proliferation (BrdU+,Olig2+) was the same in GL or WM of 
mutants and controls (Fig.2d). However, OPC proliferation in the mutant ML was 4.4 -
fold increased. Even at age 6-7 months, we found a 4.7-fold increase of 
BrdU+,Olig2+ cells. This suggests that local proliferation is stimulated (directly or 
indirectly) by GC axon-derived signals, which must still be present at older ages. At 
that time, oligodendrocyte lineage cells were 10-fold increased over controls (Fig.2d). 
By following different BrdU protocols we identified a time window (P20-30) at which 
proliferation of OPCs was already increased, but the number of (CNP+) 
oligodendrocytes was not yet altered (Fig.2e,f). This strongly suggests that OPC 
proliferation is not merely a homeostatic mechanism to replace differentiated OPCs, 
but is an early response to the neuronal trigger. Accordingly, (BrdU+,Olig2+) OPCs 
were uniformly distributed in the ML and not preferentially detected in proximity to 
newly generated (MBP+) oligodendrocytes (Fig.2g).  
 
Double-labeling for BrdU and carbonic anhydrase II (CAII), a marker of mature 
oligodendrocytes, confirmed that newly generated OPCs had responded to elevated 
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differentiation signals (Fig.2h). At 7 months, the ML in Pten-mutant brains still 
contained ‘maturating’ oligodendrocytes, as revealed by in situ hybridization of Myrf 
mRNA (Fig.2i), an early marker almost undetectable in fully mature cells (B. Emery, 
personal communication). Taken together our data suggest that Pten-mutant GC and 
thus a PI(3,4,5)P3-dependent neuronal program is sufficient to drive oligodendrocyte 
lineage cells through all developmental stages. However, we cannot formally exclude 
the theoretical possibility that normally myelinated axons recruit OPCs and induce 
myelination by completely different mechanisms. Formally, activation of neuronal 
Akt1/mTOR would not be the "initiating" event itself, if other more rate-limiting steps 
are regulated upstream. 
 
OPCs receive synaptic input that could modulate proliferation and myelination6. 
Using acute slices from mutant and control mice (additionally expressing a Ng2-
EYFP transgene7), we whole-cell patch clamped both Purkinje cells, having input 
predominantly from Pf, and fluorescent OPCs in the ML. This allowed us to 
determine GC spiking activity as well as the synaptic inputs from Pf to OPCs. 
Importantly, we found no difference between mutant and control OPCs for the 
frequency of spontaneous synaptic Pf inputs, nor the inputs to Purkinje cells (Fig.2j). 
Also the fraction of OPCs that received detectable input was not different (controls: 
39%; mutants: 47%; Χ1=0.87, p=0.4, Chi-square test). Thus, de novo myelination is 
unlikely owed to an underlying alteration of Pf spiking activity or changes of synaptic 
input to OPCs (Supplementary Fig.5; Supplementary Information).  
 
Theoretically, Pf myelination could be caused by down-regulating inhibitory neuronal 
signals. We addressed this by targeting only a small fraction of sparsely distributed 
GC, using Nex-CreERT2 mice8. After 5 days of tamoxifen (P10-15), reporter gene 
expression marked <4% of all GC (Supplementary Fig.6a). However, when analyzed 
28 weeks later (Supplementary Fig.6b), we still found a significant increase of mature 
OL and myelinated area in the ML of Nex-CreERT2*PtenloxP/loxP mice (Supplementary 
Fig.6c-f), making it highly unlikely that soluble inhibitors, still expressed by 96% of 
non-recombined GC, must be down-regulated to initiate myelination. In these mice 
de novo myelination was also observed when tamoxifen was given at age 7 months 
(not shown), arguing strongly against a critical period in development at which the 
identified PI(3,4,5)P3-dependent neuronal program can trigger myelination. 
  5 
Searching for promyelinating factors, we laser captured stripes of GL from 
cryosections of 3 months old mutants and controls for transcriptome analyses 
(Fig.3a). A resulting list of candidate genes, upregulated in Pten cKO, was further 
selected by annotation (Supplementary table1) and validated with qPCR (not shown).  
 
To confirm the significance of these findings in vivo, we tested Bdnf9, reasoning that 
its inactivation might affect de novo myelination. Surprisingly, Tg(m6)-
Cre*Ptenflox/flox*Bdnfflox/flox mice (hereafter termed Pten*Bdnf double mutants) 
exhibited a higher (not lower) number of oligodendrocytes in the ML compared to 
Pten single mutants (Fig.3b,c). Also by immunostaining, the myelinated area of the 
ML was not smaller but larger (Fig.3d,e). By EM, we confirmed that Pf calibers were 
as enlarged as in Pten single mutants (Fig.3f). However, by g-ratio analysis myelin 
was thinner in Pten*Bdnf double mutants (Fig.3g,h). Thus, in the absence of Bdnf, 
mutant oligodendrocytes are more numerous in the ML, but each fiber is only thinly 
ensheathed. Most likely, OPCs respond to either proliferation or differentiation 
signals, but not to both. In the absence of Bdnf (a differentiation signal) the weight of 
proliferation signals might increase, driving the number of OPCs up. However, 
differentiation signals will compensate later and turn all OPCs into oligodendrocytes, 
explaining a seemingly paradoxic result.  
 
To test this hypothesis directly, we compared OPC proliferation in Pten*Bdnf double 
mutants and single mutants at only 7 weeks of age, following BrdU labeling (P25-45). 
Indeed, double mutants showed 34% more BrdU-labeled (Olig2+) OPCs in the ML 
than Pten mutants (Fig.3i). Surprisingly, the lack of Bdnf even promoted proliferation 
of OPCs in heterozygous Pten mutants compared to controls (Fig.3i). This suggests 
that Bdnf helps controling the number of OPCs, which are likely to turnover in the 
absence of other myelination promoting factors. For comparison, Nrg1 (essential for 
myelination by Schwann cells1) revealed no such effects on de novo myelination in 
Tg(m6)-Cre*Ptenflox/flox*Nrg1flox/flox mice (Supplementary Fig.7).  
 
Because of the complexity of Bdnf effects in vivo, we studied other candidate factors 
(emerging from our screen) in primary oligodendrocyte cultures and myelinating 
neuron/oligodendrocyte co-cultures, using recombinant proteins to test their role in 
OPC proliferation, differentiation, and/or myelination. Indeed, Fgf1 stimulated 
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proliferation of OPCs (Supplementary Figs.8a-d and 9; Supplementary Information). 
Activin-A, the biologically active dimer of two inhibin betaA (Inhba) subunits, emerged 
as a differentiation factor10 that required MAPK (ERK1/2) to be effective, but not PI3K 
or SMAD3 (Supplementary Fig.8e-i; Supplementary Information). Also Pleiotrophin, 
Tmsb4x and Timp3 stimulated in vitro myelination (Supplementary Fig.8g,h; 
Supplementary Information).   
 
Increased axon size was further associated with upregulated expression of several 
other genes. Some mRNAs encoded secreted proteins already associated with 
oligodendrocyte development in vitro, such as Bdnf, Vegfc, and Tmsb4x9,11,12. Other 
factors, including Fstl1, IGFBP-4, Dkk-3, Apcdd1, and Sfrp4, are novel, but known 
antagonists of Wnt and Bmp signaling13,14, which inhibits oligodendrocyte 
differentiation15. Also modulators of IGF signaling and metallopeptidases (MMP17, 
Adamts1) were upregulated, the latter degrading inhibitors of remyelination. We note 
that also membrane proteins not transcriptionally upregulated may increase in 
abundance when axons grow radially.  
 
Taken together, we have identified an upstream neuronal "switch", the 
PI3K/AKT1/mTOR pathway, which is sufficient to trigger the entire program of radial 
axonal growth16, recruitment of OPCs and progressive myelination in the CNS. 
Axonal specializations, such as the clustering of Caspr at paranodal junctions, are 
part of this neuronal myelination program. C learly, myelination is triggered by a 
combination of both, the increase of axon caliber (>0.25µm) and the induced 
expression of numerous promyelinating factors. Axon caliber poses a critical 
threshold for myelination in PNS and CNS, as recently shown for cultured 
oligodendrocytes myelinating carbon nanofibers17. However, CNS myelination begins 
with OPC recruitment and expansion, followed by oligodendrocyte differentiation, all 
steps without axonal contact. Only once differentiated oligodendrocytes physically 
engulf axons, the minimum caliber is required to allow membrane wrapping. 
Schwann cells, in contrast, are always physically associated with axons and 
stimulated by a key membrane-bound growth factor, Nrg1 type III1. 
 
Down-stream of the neuronal myelination switch, not all promyelinating factors are of 
neuronal origin, in line with previous findings10. We also identified immune 
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modulatory factors upregulated, such as Nts (neurotensin) and Ninj1, previously 
implicated in immune cell migration18,19. Since moderate changes of Iba1, Mac-3, 
GFAP were detected in the mutant ML (Supplementary Fig.10a-c), we asked whether 
non-neuronal cells respond to Pten deletion in Nex-CreERT2*Ptenflox/flox mutants 
(only 4% GC recombination but significant myelination). Here, no 'gliosis' markers 
were detected in ML and GL, even 28 weeks after recombination (Supplementary 
Fig.11). Thus, de novo myelination is not dependent on any form of 'gliosis'.  
 
Moreover, several factors are expressed in endothelial cells (Supplementary table1) 
and by CD31 immunostaining we noticed increased angiogenesis in the mutant GL 
(Supplementary Fig. 10d). This is in line with the recently identified coupling of 
myelination to angiogenesis20. 
 
Importantly, not all Pten mutant neurons become myelinated as evidenced by 
hippocampal neurons in Nex-CreERT2*PtenloxP/loxP mutants. Despite efficient 
recombination of CA3 neurons8 and significant increase in the size of neuronal 
somata, Schaffer collateral axons remained unmyelinated (Supplementary Fig.12). 
This suggests a role of inhibitory signals that may 'protect' axons from myelination, 
which would interfere with sprouting and neuronal plasticity in the adult. However, we 
have no formal proof that all axons were sufficiently enlarged, as EM sections did not 
allow us to positively identify the Schaffer collaterals. 
 
In multiple sclerosis, lesioned areas fail to repair, presumably because of a poor 
balance of myelination promoting and inhibiting cues. Significant progress has been 
made in identifying small molecules targeting OPCs and oligodendrocytes in 
remyelination. Our data suggest that also neurons should be considered as 
therapeutic targets when searching for myelin repair strategies. 
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Accession Codes 
The following ImageJ plugins were used and can be freely accessed under: 
http://www1.em.mpg.de/Goebbels2016_MBP 
http://www1.em.mpg.de/Goebbels2016_GFAP 
http://www1.em.mpg.de/Goebbels2016_CoCultureMBP 
http://www1.em.mpg.de/Goebbels2016_CoCultureSmi31 
http://www1.em.mpg.de/Goebbels2016_CoCultureOlig2 
http://www1.em.mpg.de/Goebbels2016_CoCultureDapi 
 
Data Availability  
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Figure Legends 
 
Figure 1:  
 
Pten mutant GC trigger de novo myelination of Pf axons  
(a) Schematic representation of selected candidates of PI3K/AKT1/mTORC1 
signaling.  
(b) By qRT-PCR Pten transcripts containing the floxed exon 5 are decreased in the 
cerebellum of conditional Pten mutants (age 3.5 months). Means ± s.e.m. n=5 mice 
each genotype (p=0.0231, t=2.803, d.f.=8, two-tailed unpaired Student’s t-test).  
(c) On Western blots PTEN levels are decreased in the cerebellum of mutants (age 
3.5 months, cropped blot images).  
(d) Phosphorylation (p-) of the PI3K downstream effectors AKT1, GSK3, mTOR and 
S6 is enhanced in Pten mutant mice (age 3.5 months, cropped blot images).  
(e) Conditional ablation of Pten in GC causes cerebellar enlargement. 
(f) Pf have increased in diameter when analyzed by EM.  
(g) Pf caliber size distribution (n=3 mice each genotype; 140 Pf quantified per 
animal).  
(h) Myelinated Pf in the ML of mutant brains (right) immunostained for CNP (green). 
Purkinje cells (PC) and interneurons (IN) are Parvalbumin positive (red). Arrowhead 
points to an oligodendrocyte (OL) cell body. PL, Purkinje cell layer. 
(i) By EM normally unmyelinated Pf become de novo myelinated in mutant mice 
(asterisks).  
(j) Formation of a node of Ranvier (N), flanked by paranodal myelin loops (Pn; left 
panel) and septate-like junctions (right panel) with the Pf membrane at the EM level.  
(k) Progressive myelination quantified by g-ratio analysis at the indicated ages (g=1.0 
denotes unmyelinated axons, n=3 mice each genotype and age, 140 Pf quantified 
per animal). 
(l) De novo myelination of Pf requires a minimum axonal caliber of 0.25 µm.  
(m,n) Myelination of Pf includes the clustering of axonal Caspr (m, green; n, red) and 
NaV1.6 (n, green) at newly formed nodes. 
(o) Myelinated Pf synapsing on a Purkinje cell dendritic spine. "En passant" 
synapses with presynaptic vesicles (arrowhead) are restricted to newly established 
nodes.  
M, myelin; Pf, parallel fiber; Pn, paranodal loop; s, dendritic spine. e-j and l-o, age 1 
year. Images in e,f, h-j and l-o are representative of ≥ 3 similar experiments.  
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Figure 2:  
 
Pten mutant GC drive OPC proliferation in the ML 
(a) Oligodendrocytes (in red) are found in cerebellar GL but not in the ML, which 
contains only scattered NG2+ OPCs (green). Cells are labeled by DsRed and EYFP 
fluorescence in double-transgenic Plp1-DsRed*Ng2-EYFP mice.  
(b) Mature oligodendrocytes (CAII+) are more numerous in the mutant GL (p=0.0498, 
t=2.780, d.f.=4) and ML (p=0.0103, t=4.562, d.f.=4, inset), but not in WM (p=0.858, 
t=0.1907, d.f.=4). Age P45; n=3 each genotype.  
(c) OPCs in the mutant ML labeled for Olig2+ (red) and BrdU+ (green, arrowheads), 
following daily BrdU administration between P25-P45 (quantified below). 
(d) At age P45, proliferation of OPCs (BrdU+,Olig2+) is increased in the mutant ML 
(p=0.0004, t=25.49, d.f.=4), and remains elevated at P201 (following daily BrdU 
administration between P181-P201; p=0.0016, t=10.98, d.f.=4). Note that the number 
of Olig2+ cells at P201 is 10-fold higher than in controls (p=0.0031, t=11.37, d.f.=4). 
WM, p=0.8581, t=0.1907, d.f.=4; GL, p=0.4133, t=0.9122, d.f.=4; n=3 each genotype 
and age. 
(e,f) Following daily BrdU administration (P15-P20) the number of proliferating OPCs 
(BrdU+,Olig2+) in the ML is similar in mutants and controls (in e; p=0.3161, t=1.145, 
d.f.=4). While at age P30 (and after daily BrdU administration between P20 and P30) 
the number of proliferating OPCs (BrdU+,Olig2+) in the ML is increased in the 
mutants (left panel in f; p=0.0120, t=4.364, d.f.=4), the number of CNP+ 
oligodendrocytes is not (right panel in f, p=0.8025, t=0.2673, d.f.=4). n=3 each 
genotype and age. 
(g) Following daily BrdU administration (P25-P45) labeled OPCs (asterisks) distribute 
evenly and are not preferentially close to newly generated oligodendrocytes and their 
myelin sheaths (arrowheads).  
(h) After daily BrdU injections (P25-P45) mature oligodendrocytes can be co-labeled 
for BrdU (green) and CAII (red). n=3 each genotype (p=0.0006, t=9.839, d.f.=4). 
(i) By in situ hybridization, Myrf mRNA can sti ll be detected in the adult Pten mutant 
ML (positive control, wildtype cerebellum P20). 
(j) Representative traces of spontaneous postsynaptic inward currents recorded from 
NG2-EYFP expressing OPCs clamped at -74mV in the ML of (a) control mice and (b) 
Pten mutant mice (a’, b’, inward currents at an expanded time scale); (c) frequency of 
detectable spontaneous events in OPCs plotted against the age of the animal. The 
slopes are not significantly different between control (blue, n=42 cells from 25 
animals of 12 different litters) and mutant mice (red, 28 cells from 17 animals of 11 
litters) (p=0.2, F=1.625, d.f.=66, linear regression). (d) Similarly, there is no 
significant difference in the frequency of spontaneous inputs in Purkinje cells (PC) 
which are predominantly from Pf (control, 0.9±0.1 Hz, n=5 cel ls from 2 animals of 1 
litter; mutant, 0.7±0.2 Hz, n=4 cells from 1 animal of 1 litter; p=0.36, t=2.13, d.f.=10).  
Data are means ± s.e.m. *p<0.05; **p<0.01; ***p<0.001, two-tai led unpaired 
Student’s t-test (in b,d,e,f,and h), chi-square test (in jd), Analysis of covariance 
(ANCOVA) (in jc). GL, GC layer; ML, molecular layer; WM, white matter. Images in 
a,c and g-i are representative of 3 similar experiments. 
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Figure 3:  
 
Screen for candidate promyelinating factors and validation of Bdnf  
(a) Experimental design to identify and test candidate factors (see Supplementary 
Information) that may regulate oligodendrocyte development in conditional GC-
specific Pten mutant mice. Laser capture microdissection (LCM) was used to obtain 
the GL from serial cerebellar sections at age 3 months.  
(b-e) Double mutants lacking both PTEN and Bdnf in GC harbor more CNP+ 
oligodendrocytes in the ML (arrowheads in b, c: 7 weeks, control vs. Pten het*Bdnf 
cKO, p=0.0495, t=2.786; control vs. Pten cKO, p<0.0001, t=28.25; Pten cKO vs. Pten 
cKO*Bdnf cKO, p=0.0132, t=3.757, d.f.=13, F=56.01; 10 weeks, control vs. Pten 
het*Bdnf cKO, p=0.1530, t=1.684; control vs. Pten cKO, p<0.0001, t=55.87; Pten 
cKO vs. Pten cKO*Bdnf cKO, p=0.0012, t=6.661, d.f.=13, F=1895) and exhibit a 
larger MBP+ myelinated area (d, e: 7 weeks, control vs. Pten het*Bdnf cKO, 
p=0.4886, t=0.7619; control vs. Pten cKO, p=0.0085, t=4.196; Pten cKO vs. Pten 
cKO*Bdnf cKO, p=0.0024, t=5.021, F=40.64, d.f.=13; 10 weeks, control vs. Pten 
het*Bdnf cKO, p=0.3938, t=0.9547; control vs. Pten cKO, p=0.0039, t=5.979; Pten 
cKO vs. Pten cKO*Bdnf cKO, p=0.0476, t=2.611, F=23.02, d.f.=12) compared to 
single Pten mutants (quantitated on parasagittal sections of the cerebellar vermis; 
n=3-4 each genotype at indicated ages).  
(f) By EM of Pten*Bdnf double mutants and single Pten mutants, axon sizes are 
unchanged in both myelinated (p=0.4339, t=0.869, d.f.=4) and unmyelinated Pf 
(p=0.5558, t=0.642, d.f.=4; age 10 weeks; n=3 each genotype). 
(g-h) G-ratio analysis of ML myelin in Pten single mutants and Pten*Bdnf double 
mutants (p=0.0259, t=3.454, d.f.=4; 250-490 myelinated Pf per animal; n=3 each 
genotype; age, 10 weeks).  
(i) BrdU administered from P25-P45 and histology performed 4 days later. The 
number of BrdU+,Olig2+ cells is higher in Pten*Bdnf double mutants compared to 
Pten single mutants (control vs. Pten het*Bdnf cKO, p=0.0419, t=2.74; control vs. 
Pten cKO, p<0.0001, t=16.53; Pten cKO vs. Pten cKO*Bdnf cKO, p=0.0426, t=2.565, 
F=56.01, d.f.=13; quantified in the ML of parasagittal sections of the cerebellar 
vermis; n=3-4 each genotype). 
Data are means ± s.e.m. *p<0.05; **p<0.01; ***p<0.001, two-tai led unpaired 
Student’s t-test (in f,h) or one-way analysis of variance (ANOVA) followed by 
Bonferroni test (in c,e, and i). GL, granule cell layer; ML, molecular layer. Images in 
a,b and d are representative of ≥3 similar experiments. 
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Online Methods 
 
Mouse mutants 
All experiments were conducted according to the Lower Saxony State regulations for 
the use of experimental animals in Germany as approved by the Niedersächsische 
Landesamt für Verbraucherschutz und Lebensmittelsicherheit (LAVES) and 
according to UK government animal use regula tions. Mice were housed in groups in 
individually ventilated cages under a 12:12h light/dark cycle with access to food and 
water ad libitum. If not stated otherwise, for molecular, histological, 
electrophysiological, electron microscopical and biochemical experiments, female 
and male mice were included in the experiments and were randomly allocated to 
experimental groups according to age and genotype. All animal experiments were 
conducted in a single blinded fashion towards the investigator. Inclusion/exclusion 
criteria were pre-established. Animals were excluded from the experiment when 
showing impaired health conditions not attributable to genotype or experiment or 
when the weight difference to the average group weight was larger than 10%. With 
respect to the outcome assessment, exclusion criteria were determined with Grubbs' 
test (ESD method), using the statistical software GraphPad (Prism). No animals or 
samples had to be excluded with these criteria in any of the experiments. 
 
Mice mutant for Ptenflox/flox, Tg(m6-Cre)B1LFR, Nex-CreERT2, Nrg1flox/flox, 
Bdnfflox/flox, Plp1-DsRed, Rosa26-lacZ and Ng2-EYFP were genotyped as 
described4,5,7,8,21-24. Tg(m6-Cre)B1LFR, Nex-CreERT2, Nrg1flox/flox, Bdnfflox/flox, Plp1-
DsRed, Rosa26-lacZ and Ng2-EYFP mutants were on C57BL/6N background, 
whereas Ptenflox/flox mutants and thus all compound mutants harboring Ptenflox alleles 
were on mixed C57BL/6N-SV129 background. For genotyping, genomic DNA was 
isolated from tail biopsies (InvisorbSpin Tissue Mini kit, Invitek) according to the 
manufacturer’s directions and subjected to routine PCR methods using the following 
primers: 
Pten sense 5'-ACTCAAGGCAGGGATGAGC-3' 
antisense 5'-CAGAGTTAAGTTTTTGAAGGCAAG-3' 
Tg(m6-Cre)B1LFR sense 5'-TAGAGCATTAGGGTGGGAG-3' 
antisense 5'-TGCCGCCTTTGCAGGTGTGTCTTAC-3' 
Nrg1 sense 5'-GCACCAAGTGGTTGCGATTGTTGCT-3' 
antisense 5'-TCCTTTTGTGTGTGTTCAGCACCGG-3' 
Bdnf sense 5'-GTTGCGTAAGCTGTCTGTGCACTGTGC-3' 
antisense 5'-CAGACTCAGAGGGCACTTTGATGGCTTG-3' 
Plp1-DsRed sense 5'-CGCCGACATCCCCGACTACAA-3' 
antisense 5'-GCGGCCGCTACAGGAACAGGT-3' 
Rosa26-lacZ sense 5'-AAAGTCGCTCTGAGTTGTTAT-3' 
antisense 5'-GCGAAGAGTTTGTCCTCAACC-3' 
Ng2-EYFP sense 5'-TGACCTTGGATTCTGAGC-3' 
antisense 5'-CGCTGAACTTGTGGCCGTTTA-3' 
 
BrdU labeling 
Mice received 5’-bromo-deoxyuridine (BrdU, Sigma Aldrich) by daily intraperitoneal 
injections (50 µg/g of body weight) for 5, 10, or 20 consecutive days. Mice were 
sacrificed 4 hours or 4 days post final injection. 
 
Histology and immunohistochemistry 
Mice were anaesthetized with avertin (Sigma–Aldrich) and perfused with 15 ml of 
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Hanks balanced salt solution (HBSS, PAA laboratories, Pasching, Austria) followed 
by fixative (4% PFA, 0.1M Phosphate buffer, 0.5% NaCl). Paraffin sections of the 
brain (5 µm) were deparaffinized using xylene and isopropanol and rehydrated in a 
descending ethanol series. Antigen unmasking was performed by boiling for 10–40 
min in citric buffer, pH 6, or Tris EDTA, pH 9. Sections were blocked in 20% goat 
serum in PBS/BSA for 1 h and incubated with primary antibodies in 5% goat serum in 
PBS/BSA for 2 h at 37°C or overnight at 4°C. Detection was performed by using 
Alexa Fluor 488-, 555- and 633-conjugated secondary antibodies (1:1000, Thermo 
Fisher Scientific, #A-28175, #A-11034, #A-21212, #A-21422, #A-27039 and #A-
21094) and by using biotinylated secondary antibodies, followed by diaminobenzidine 
(DAB) (LSAB2 Kit, Dako, #K0675; Vectastain Kit, Vector Laboratories, #BA-9400, 
#PK-6100). Primary antibodies were directed against BrdU (1:200, Chemicon, 
#MAB3424), CAII (1:200, kindly provided by S. Ghandour, Strasbourg, PMID: 
118210), Calbindin (1:600, Sigma, #C9848), Caspr (1:100, NeuroMab, #75-001), 
CD31 (1:100, Dianova, #DIA-310), CNP (1:150, Sigma, #C5922), GABAA receptor 6 
subunit (1:500, Chemicon, #AB5610), GFAP (1:200, Novocastra, #NCL-GFAP-GA5), 
Iba1 (1:1000, Wako, #019-19741), MBP (1:200, Covance, #SMI-94R); NaV1.6 (1:500, 
Alomone Labs, #ASC-009); NeuN (1:200, Chemicon, #MAB377); Olig2 (1:200, kindly 
provided by J. Alberta, PMID: 15198128), and Mac-3 (1:500, BD Pharmingen, 
#553322). 5 µm microtome sections (Microm HM400) were also stained by 
hematoxylin–eosin (HE) to study cytoarchitecture. Myelinated fibers were visualized 
by Gallyas silver impregnation as described25. All images showing 
immunohistochemical analyses and stainings were successfully repeated at least 
three times. iDISCO whole-mount anti-CNP immunohistochemistry was performed 
according to the published protocol26 on dissected cerebella from control and mutant 
animals. Monoclonal anti-CNP primary antibody (1:200, Sigma, #C5922) was used 
with a 4 days incubation at 37°C. Donkey anti-mouse Alexa Fluor 647-conjugated 
secondary antibody (1:1000, Life Technologies, #A-31571) was used for 4 days at 
37°C. After clearing, samples were imaged on a LaVision Ultramicroscope II with a 
2X 0.5NA objective and on an Olympus FV-1000 2 photon microscope with a 25X 
1.05NA water immersion objective, and a laser tuned at 820nm. Image stacks were 
analyzed with Imaris 8.01 (Bitplane). 
 
In situ hybridization  
In situ hybridization was performed as described27. A Myrf probe corresponding to 
941bp from Myrf 3’ UTR was kindly provided by B. Emery. 
 
Electron microscopy 
Mice were anaesthetized with avertin (Sigma–Aldrich) and perfused with 15 ml of 
Hanks balanced salt solution (HBSS, PAA laboratories, Pasching, Austria) followed 
by fixative (4% PFA, 0.1M Phosphate buffer, 0.5% NaCl, 2.5% glutaraldehyde). At 
parasagittal plane, cerebellar lobulus 5 was dissected, contrasted with 1% osmium 
tetraoxide and embedded in epoxy resin. Semi-thin (0.5mm) and ultra-thin (50–60 
nm) sections were cut, using a microtome (RM 2155, Leica Microsystems, Wetzlar, 
Germany) with a diamond knife (Histo HI 4317, Diatome, Biel, Switzerland). Semi -
thin sections were stained with azur-II-methylenblue for 1 min at 60°C. Ultra-thin 
sections were stained with 2% uranylacetate (30 min) and 1% lead citrate solution 
(12 min) and analyzed using a LEO EM912AB electron microscope (Carl Zeiss NTS, 
Oberkochen, Germany). Images were taken with an on-axis 2048x2048 CCD camera 
(Proscan, Scheuring, Germany). 
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Electrophysiology  
Parasagittal cerebellar slices (225 μm) were cut using a vibrating blade microtome 
(Leica VT1200S) from P7-P100 Ng2-EYFP+/-*Tg(mα6)-Cre*PtenloxP/loxP mice 
(mutants) and Ng2-EYFP+/-*Pten loxP/loxP mice (controls), culled by cervical dislocation 
in accordance with UK government animal use regulations. After dissection, the brain 
was placed in a cooled (∼1ºC) oxygenated (95% O2–5% CO2) Krebs solution 
containing (mM): 126 NaCl, 24 NaHCO3, 1 NaH2PO4, 2.5 KCl, 2.5 CaCl2, 2 MgCl2, 
10 D-glucose (pH 7.4). In addition, kynurenic acid was included in order to block 
glutamate receptors, which might be activated during the dissection procedure and 
cause cell damage. During experiments slices were superfused at 22±1ºC with 
HEPES- buffered external solution containing (mM): 144 NaCl, 2.5 KCl, 10 HEPES, 1 
NaH2PO4, 2.5 CaCl2, 10 glucose, 0.1 glycine (to co -activate NMDA receptors), 
0.005 strychnine (to block glycine receptors), pH set to 7.4 with NaOH, bubbled with 
100% O2. OPCs were identified by EYFP expression and whole-cell voltage 
clamped. Recording electrodes had a resistance between 5-9MΩ when fi lled with an 
internal solution comprising (mM): 130 K-gluconate, 4 NaCl, 0.5 CaCl2, 10 HEPES, 
10 BAPTA, 4 MgATP, 0.5 Na2GTP, 2 K-Lucifer yellow, pH set to 7.3 with KOH and 
the uncompensated series resistance was 40±1MΩ and electrode junction potentials 
(- 14mV) were compensated for. A Multiclamp 700B (Molecular Devices) was used 
for voltage clamp data acquisition. Data were sampled at 50kHz and filtered at 10kHz 
using pClamp10.3 (Molecular Devices). 
 
Synaptic current analysis 
A synaptic current was defined to occur if its amplitude was bigger than twice the 
standard deviation of the baseline current noise and its 10-90% decay time was 
longer than its rise time. Events were detected and analyzed with pClamp 10.3 
(Molecular Devices) and the Strathclyde Electrophysiology Software package 
WinEDR V3.3.7 WinWCP V4.6.2. 
 
Laser-capture microdissection, RNA isolation and linear amplification, and microarray 
hybridization 
Mice were killed at 3 months of age by cervical dislocation, total brains were 
dissected and frozen on dry ice, protected with parafilm and stored at -80°C. Serial 
coronal cryosections (20 µm) were prepared using a Leica CM3000 Cryostat, 
mounted on polyethylene naphthalate membrane frame slides (Arcturus), stained 
with thionin, and dried in an ascending ethanol/xylene series. For laser-capture 
microdissection (LCM), a Veritas Microdissection System (Arcturus) was used with 
slides mounted and stained the same day. Cerebellar GL were dissected by 
ultraviolet laser (laser power set to 3.2–4.2) and attached to CapSure LCM caps 
using an infrared laser (power set to 80%). Caps were collected in 0.5 ml Eppendorf 
tubes containing 100 µl of RNeasy Lysis Buffer (Qiagen) and stored at -80°C. Total 
RNA was isolated from LCM tissue using the Micro RNeasy Kit (Qiagen) according to 
the instructions of the manufacturer except that RNA was eluted from the column 
with 10µl of water followed by precipitation with NaAcetate (pH 5.2, f.c. 0.3M) and 
PelletPaint (Novagen) as carrier. Two-round amplification and biotin-labeling, 
hybridization to mouse MOE230A 2.0 genechips (Affymetrix), washing and scanning 
was essentially as described28 with 3 biological replicates for each genotype. Data 
analysis was performed using Genomics Suite (Partek Inc.). Raw data were 
normalized using the RMA algorithm and differentially expressed genes were 
identified with ANOVA according to the workflow suggested by the manufacturer 
(Partek Inc.). Differentially expressed genes with signal intensities in mutants > 
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controls were selected with >1.4-fold change and adjusted P-values <0.05. 
 
RNA isolation, cDNA synthesis, and qRT-PCR.  
Total RNA was isolated from LCM tissue using the Transcriptor High Fidelity Kit 
(Roche) according to the instructions of the manufacturer. cDNA was synthesized 
using a mixture of random nonamer primers and anchored poly-dT primers and 
SuperScript III RNase H reverse transcriptase (Invitrogen) according to the 
instructions of the manufacturer. qRT-PCR was performed using SYBR green master 
mix (Applied Biosystems) and a 7500 Fast Real-Time PCR System (Applied 
Biosystems). Primers were designed using the Roche Universal ProbeLibrary 
website (http://qpcr.probefinder.com). Primer sequences are available upon request. 
Relative mRNA concentrations were normalized to Actin and Atp5b. Data were 
analyzed using qBase software version 1.3.5 (Center for Medical Genetics, Ghent 
University, Ghent, Belgium). 
 
Mixed myelinating cocultures from mouse spinal cord  
Wild-type C57BL/6N mice were time-mated, with the day of plugging denoted as 
embryonic day 0.5 (E0.5), and embryos were collected on embryonic day 13.5 
(E13.5). The spinal cord was dissected, and dissociated mechanically and 
enzymatically (0.25% trypsin, Invitrogen). Enzymatic activity was stopped by the 
addition of plating medium (50% DMEM, 25% horse serum, 25% Hanks balanced 
salt solution without Ca2+ and Mg2+) containing 2.5 µg/ml DNAse I. Cells were 
dissociated into a single cell suspension by triturating through 20- and 23-gauge 
needles (4 and 2 times, respectively) and spun at 800 rpm for 5 min. The pellet was 
resuspended in plating medium. Dissociated spinal cord cells were plated initially 
onto poly-L-lysine (PLL, in boric acid buffer, pH8.4) coated coverslips at a density of 
150.000 cells/100 µl, which were then placed into a 35-mm Petri dish. The cells were 
left to attach for 2–3 hours, when 150 µl of plating medium and 500 µl of 
differentiation medium was added. This medium contained DMEM (4,500 mg/L 
glucose), 10 mg/ml biotin, 0.5% hormone mixture (1 mg/mL apotransferrin, 20 mM 
putrescine, 4 µM progesterone, and 6 µM selenium), 50 nM hydrocortisone, and 10 
g/ml insulin (all reagents were from Sigma). Cultures were maintained by replacing 
half of the medium with fresh medium three times a week. After 12 days in culture, 
cells were fed with differentiation medium with (or without) recombinant human Pdgf 
(100ng/ml), Sparcl1 (10ng/ml), Vegfc (100ng/ml), Fgf1 (100ng/ml), Ptn (10ng/ml), 
Timp3 (100ng/ml), Tmsb4x (50ng/ml) or Activin A (100 ng/ml) and reduced 
concentration of Insulin (0.2 g/ml). Cultures were maintained for up to 25 days in a 
humidified atmosphere of 5% CO2 at 37°C.  
 
Mixed primary oligodendrocyte cultures  
Mixed primary oligodendrocyte cultures were prepared from (7 pooled) spinal cords 
of P4 mouse pups. Tissue chunks were incubated in 5 ml papain (200U) in papain 
buffer plus L-cysteine for 1 hour at ~35°C with constant gassing (95% oxygen and 
5% carbon dioxide). The papain reaction was stopped with plating medium (30% 
horse serum in DMEM) containing 2.5 µg/ml DNAse I. Cells were dissociated into a 
single cell suspension by triturating through 20 and 23 gauge needles (4 and 2 times, 
respectively), spun at 800 rpm for 5 min, and the pellet was resuspended in plating 
medium. Cells were plated at a concentration of 80,000 cells/100 µl plating medium 
onto PLL coated 11 mm diameter glass coverslips, in 35 mm diameter Petri -dishes (2 
coverslips/dish). Two hours later, differentiation medium containing DMEM (4,500 
mg/L glucose), 10 ng/ml biotin, 0.5% hormone mixture (1 mg/mL apotransferrin, 20 
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mM putrescine, 4 µM progesterone, and 6 µM selenium), 50 nM hydrocortisone, and 
10 g/ml insulin (all reagents from Sigma) was added to each 35 mm Petri dish to 
yield a mix of 50% plating medium: 50% differentiation medium. The following day all 
medium and myelin debris was removed from the coverslips by rinsing briefly in 
medium, and fresh differentiation medium was added to each 35 mm Petri dish, with 
or without human recombinant forms of Klotho (400ng/ml), Ptn (10ng/ml), Timp3 
(100ng/ml) or Activin A (100ng/ml). Cells were fed every second day by replacing half 
the medium with fresh differentiation medium including the recombinant proteins. 
Cultures were maintained for 3 and 5 days in a humidified atmosphere of 5% CO2 at 
37°C.  
 
Recombinant proteins 
Human recombinant proteins were Sparcl1, Vegfc, Klotho, Timp3, and Activin A 
(R&D Systems), Pdgf and Ptn (Sigma Aldrich), Tmsb4x (Novus Biologicals) and Fgf1 
(Invitrogen). Recombinant proteins were dissolved in ddH2O. Individual aliquots were 
thawed only once and diluted in cell culture medium immediately before use. PI3K 
inhibitor LY294002 and MEK1/2 inhibitor UO126 were from Cell Signaling 
Technology, SMAD3 inhibitor SIS3 was from Calbiochem. 
 
Immunocytochemistry 
Cell were fixed with 4% PFA for 5 min at 37°C. After fixation, cultures were washed in 
PBS three times, permeabilized with ice cold methanol for 5 min, and blocked in 
blocking buffer (2% fish skin gelatin, 2% FCS, 2% BSA in PBS) for 60 min. Primary 
antibodies (diluted in 10% blocking buffer) were directed against GFAP (1:200, 
Novocastra, #NCL-GFAP-GA5), KI-67 (1:10, Dako, #M7249), MBP (1:200, Covance, 
#SMI-94R), Olig2 (1:200, kindly provided by J. Alberta, PMID: 15198128) SMI31 
(1:1000, Covance, #SMI-31P), and APC-CC1 (1:100, Calbiochem, #OP80) and 
incubated overnight at 4°C. Coverslips were washed in PBS three times. 
Corresponding secondary Alexa Fluor 488-, 555- and 633-conjunated antibodies 
(1:1000, Thermo Fisher Scientific, #A-28175, #A-21422, #A-27039 and #A-21094) 
were diluted in 10% blocking buffer and added for 1 h. Coverslips were washed in 
ddH2O three times and mounted in Aqua-Poly/Mount (Polysciences). 
 
Morphometry  
Digitized overlapping light microscopic images (20x) were fused to a continuous 
image of a complete parasagittal cerebellum (Lateral, 0.12 mm) by using Zeiss Zen 
software and analyzed for absolute numbers of CNP+, CAII+, Olig2+, Iba1+, Mac-3+, 
and BrdU+ cells. The number of Iba1+ and Mac-3+ cells was normalized to the area 
of ML and GL, respectively. Endothelial cells positive for CD31 were traced with 
ImageJ and normalized to the area of the ML. To quantify MBP+ and GFAP+ areas, 
two ImageJ plugins for semi-automated analysis were implemented 
(www1.em.mpg.de/Goebbels2016_MBP, www1.em.mpg.de/Goebbels2016_GFAP). 
Average diameter of hippocampal CA3 neuronal cell bodies of Nex-
CreERT2*PtenloxP/loxP mice was determined by using ImageJ software. Two 
independent sections per mouse and staining were quantified. In cell culture 
experiments, the differentiation and proliferation state of oligodendrocyte lineage 
cells was analyzed within the given fields of 11 randomly taken images (20x) per 
coverslip (mixed myelinating cultures: myelination assay, 3-11 independent 
experiments with 2 coverslips per condition; proliferation assay, 3-11 independent 
experiments with 1 coverslip per condition; mixed primary oligodendrocyte cultures: 
3-5 independent experiments with 2 coverslips per condition). For quantitative 
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assessment of in vitro myelination a ‘myelination index’ was calculated by dividing 
the MBP+ area (as identified by generating a ‘mask’ outlining the myelin sheaths; 
ImageJ plugin: www1.em.mpg.de/Goebbels2016_CoCultureMBP) by the axonal area 
(Smi31+ axons; ImageJ plugin: 
http://www1.em.mpg.de/Goebbels2016_CoCultureSmi31). For the proliferation assay 
the percentage of semi-automatically quantified Olig2+ cells was determined in 
relation to all DAPI+ cells (Olig2: ImageJ plugin: 
http://www1.em.mpg.de/Goebbels2016_CoCultureOlig2; Dapi: ImageJ plugin: 
http://www1.em.mpg.de/Goebbels2016_CoCultureDapi) and the number of Ki67+, 
Olig2+ cells was set in relation to the total number of Olig2+ cells. For the 
differentiation assay, the percentage of postmitotic oligodendrocytes was determined 
by quantifying and dividing the numbers of CC1+ cells by the total number of Olig2+ 
oligodendrocyte lineage cells. All analyses were performed in a single blinded 
fashion towards the investigator who was unaware of the treatment regimen. 
 
G-ratio measurement 
Digitized images (magnification 7000x) of ultrathin cerebellum lobe 5 sections were 
used to determine the numbers of myelinated axons, axon calibers and g-ratios 
(>100 randomly chosen myelinated axons in the ML). g-ratios were determined by 
dividing axon diameter by the diameter of the entire fiber (in Fig.1k) or by dividing the 
inner myelin diameter by the diameter of the entire fiber (in Fig.3g and 
Supplementary Fig.7c). Quantitations were performed from ≥3 age-matched male 
mice per genotype and age.  
 
Protein Analysis 
Cerebellum lysates were homogenized in lysis-buffer (50 mM HEPES, pH 7.5, 150 
mM NaCl, 1.5 mM MgCl2, 5 mM EGTA, 10% glycerol, 1% triton X-100, 2mM 
Na3VO4) containing phosphatase (PhosSTOP Inhibitor Cocktail, Roche, Basel, 
Switzerland) and protease (Complete tablets, Roche, Basel, Switzerland) inhibitors 
using an Ultraturrax (T8, Ika, Staufen, Germany) at highest settings (30–60 s). After 
incubation for 15 min on ice insoluble material was removed by centrifugation at 
16.000 g, 4°C for 15 min. For Westernblot analysis, 10 µg of protein lysate was size -
separated on 12% of SDS-polyacrylamide gels and blotted onto PVDF membranes 
(HybondTM-P, Amersham Biosciences, UK) by Bio-Rad western blotting method. 
Membranes were blocked in 5% milk powder (in PBS) for 1h at room temperature. 
Primary antibodies were directed against p-AKT1 (Cell Signaling, mRb, 1:1000, 
#4060), AKT1 (Cell Signaling, mRb, 1:1000, #4691), PTEN (Cell Signaling, mRb, 
1:1000, #9188), p-GSK3 (Cell Signaling, mRb, 1:1000, #9336), p-mTOR (Cell 
Signaling, mRb, 1:1000, #5536), p-S6 (Cell Signaling, mRb, 1:1000, #4858), and 
Actin (Sigma–Aldrich, mM, 1:1000, #A3853). Antibodies were diluted in blocking 
buffer and incubated overnight at 4°C. Membranes were washed 3 x 10 min in TBS-T 
buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl and 0.05% Tween-20), followed by an 
incubation with horse-radish peroxidase-conjugated secondary antibodies (1:5000, 
Dianova, #111-035-003, #115-035-003). After three more washing steps with TBS-T 
buffer, immunoreactive proteins were detected with an enhanced chemiluminescence 
kit (Western LightningTM, Westernblot Chemiluminescence Reagent Plus, 
PerkinElmer Life Sciences, Waltham, MA) according to the manufacturer’s 
instructions. 
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Statistical analysis 
For Power analysis the software G*Power Version 3.1.7. was used. Power analyses 
were performed before conducting experiments (a priori). Adequate Power (1 – beta-
error) was defined as ≥ 80% and the alpha error as 5%. The sample size was 
calculated with the following pre-specified effect sizes: 1. mRNA expression analysis: 
effect size d of approximately 2.5 (estimated mean difference of 50% and standard 
deviation of 15%). 2. Analysis of mature oligodendrocyte numbers in GL (effect size d 
of approximately 3.5, estimated mean difference of 30% and standard deviation of 
10%) and ML (effect size d of approximately 6.5, estimated mean difference of 400% 
and standard deviation of 30%) and myelinated area in the ML of wildtype and Pten 
mutants (effect size d of approximately 6.0, estimated mean difference of 170% and 
standard deviation of 40%). 3. Proliferation analysis of oligodendrocyte lineage cells: 
effect size d of approximately 9.0 (estimated mean difference of 330% and standard 
deviation of 15%). 4. In vivo analysis of candidate genes. Analysis of mature 
oligodendrocyte numbers: effect size d of approximately 5.5 (estimated mean 
difference of 30% and standard deviation of 15%). Analysis of myelinated area: effect 
size d of approximately 4.0 (estimated mean difference of 30% and standard 
deviation of 13%). Proliferation analysis of oligodendrocyte lineage cells: effect size d 
of approximately 3.5 (estimated mean difference of 20% and standard deviation of 
10%). Analysis of (i) myelinated and (ii) unmyelinated pf diameters: (i) effect size d of 
approximately 2.6 (estimated mean difference of 20% and standard deviation of 
13%). (ii) Effect size d of approximately 1.5 (estimated mean difference of 15% and 
standard deviation of 13%). G-ratio analysis: effect size d of approximately 4.5 
(estimated mean difference of 6% and standard deviation of 2%). 5. Microglia (ML: 
Effect size d of approximately 4.7, estimated mean difference of 100% and standard 
deviation of 20%; GL: effect size d of approximately 1.2, estimated mean difference 
of 10% and standard deviation of 5%), astrocytes (ML: effect size d of approximately 
4.0, estimated mean difference of 150% and standard deviation of 15%; GL: effect 
size d of approximately 1.3, estimated mean difference of 10% and standard 
deviation of 5%) and vascular endothelia cells (effect size d of approximately 3.7, 
estimated mean difference of 40% and standard deviation of 15%) in Pten mutant 
mice. 6. Microglia (ML: effect size d of approximately 1.0, estimated mean difference 
of 10% and standard deviation of 9%; GL: effect size d of approximately 1.3, 
estimated mean difference of 10% and standard deviation of 7%) and astrocytes 
(ML: effect size d of approximately 1.2, estimated mean difference of 20% and 
standard deviation of 15%; GL: effect size d of approximately 1.1, estimated mean 
difference of 10% and standard deviation of 5%) in NEX-CreERT2*PtenloxP/loxP mice. 
7. Average diameter of hippocampal CA3 neuronal cell bodies from Nex-
CreERT2*PtenloxP/loxP mice: effect size d of approximately 12.0 (estimated mean 
difference of 25% and standard deviation of 2%) 8. In vitro analysis of candidate 
factors. Analysis of oligodendrocyte lineage cell numbers: effect size d of 
approximately 4.0 (estimated mean difference of 80% and standard deviation of 
30%). Proliferation analysis: effect size d of approximately 2.3 (estimated mean 
difference of 60% and standard deviation of 36%). Myelination index: effect size d of 
approximately 2.0 (estimated mean difference of 65% and standard deviation of 
50%). Analysis of oligodendrocyte differentiation: effect size d of approximately 9.0 
(estimated mean difference of 40% and standard deviation of 10%). For 
electrophysiology experiments we determined the sample size by uti lizing previous 
data distributions. 
Data are expressed as means +/- s.e.m. In order to select appropriate statistical tests 
all data have been tested for normal distribution with Kolmogorov-Smirnov test or 
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Shapiro-Wilk test. For normally distributed data with comparable variances we used 
two-tailed unpaired Student’s t-tests and Chi-square tests to determine the statistical 
significance between two groups. For data not showing normal distribution or in case 
that no normality test could be conducted the nonparametric Wilcoxon matched pairs 
test was applied. Data sets containing more than two groups were tested by applying 
analysis of variance (ANOVA) and Bonferroni post hoc test. Analysis of co-variance 
(ANCOVA) was used to analyze the differences between slopes of regression lines. 
Applied statistical tests are indicated in the respective figure legends. Statistical 
differences were considered significant when p<0.05 (*p<0.05, **p<0.01, ***p<0.001) 
and tests and fitting of regression lines were performed by using GraphPad (Prism) 
and MS Excel.  
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